Impact of adjuvant chemotherapy on long-term overall survival in patients with high-risk stage II colon cancer: a nationwide cohort study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/CAAC.21660.
   PubMed Web of Science ®Google Scholar
• Pahlman LA, Hohenberger WM, Matzel K, et al. Should the benefit of adjuvant chemotherapy in colon cancer be re-evaluated? J Clin Oncol. 2016;34(12):1297–1299. doi: 10.1200/JCO.2015.65.3048.
   PubMed Web of Science ®Google Scholar
• Wong MCS, Huang J, Lok V, et al. Differences in incidence and mortality trends of colorectal cancer worldwide based on sex, age, and anatomic location. Clin Gastroenterol Hepatol. 2021;19(5):955–966.e61. doi: 10.1016/J.CGH.2020.02.026.
   PubMed Web of Science ®Google Scholar
• QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–2029. doi: 10.1016/S0140-6736(07)61866-2.
   PubMed Web of Science ®Google Scholar
• Jeffery M, Hickey BE, Hider PN, et al. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2016;11(11):CD002200. doi: 10.1002/14651858.CD002200.PUB2/MEDIA/CDSR/CD002200/REL0002/CD002200/IMAGE_N/NCD002200-CMP-009-01.PNG.
   PubMedGoogle Scholar
• Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23(34):8664–8670. doi: 10.1200/JCO.2005.01.6071.
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Bermann A, Rettig K, et al. 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Ann Oncol. 2003;14(3):395–399. doi: 10.1093/ANNONC/MDG100.
   PubMed Web of Science ®Google Scholar
• André T, De Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015;33(35):4176–4187. doi: 10.1200/JCO.2015.63.4238.
   PubMed Web of Science ®Google Scholar
• Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–1471. doi: 10.1200/JCO.2010.33.6297.
   PubMed Web of Science ®Google Scholar
• Baxter NN, Kennedy EB, Bergsland E, et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J Clin Oncol. 2022;40(8):892–910. doi: 10.1200/JCO.21.02538.
   PubMed Web of Science ®Google Scholar
• Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev. 2008;2008(3):CD005390. doi: 10.1002/14651858.CD005390.PUB2.
   PubMedGoogle Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422. doi: 10.1093/ANNONC/MDW235.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/dukes’ B2 colon cancer. J Clin Oncol. 1995;13(12):2936–2943. doi: 10.1200/JCO.1995.13.12.2936.
   PubMed Web of Science ®Google Scholar
• Erlichman C, O’Connell M, Kahn M, et al. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International multicentre pooled analysis of B2 colon cancer trials (IMPACT B2) investigators. J Clin Oncol. 1999;17(5):1356–1363. doi: 10.1200/jco.1999.17.5.1356.
   PubMed Web of Science ®Google Scholar
• Babcock BD, Aljehani MA, Jabo B, et al. High-risk stage II colon cancer: not all risks are created equal. Ann Surg Oncol. 2018;25(7):1980–1985. doi: 10.1245/S10434-018-6484-8.
   PubMed Web of Science ®Google Scholar
• Kannarkatt J, Joseph J, Kurniali PC, et al. Adjuvant chemotherapy for stage II colon cancer: a clinical dilemma. J Oncol Pract. 2017;13(4):233–241. doi: 10.1200/JOP.2016.017210.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Chu E. Adjuvant chemotherapy for stage II colon cancer: the debate goes On. J Oncol Pract. 2017;13(4):245–246. doi: 10.1200/JOP.2017.022178.
   PubMed Web of Science ®Google Scholar
• Klinisk Retningslinje │Kraeft DCCG. 2021. Available from: https://dccg.dk/wp-content/uploads/2021/01/DCCG_Adj-KRC_st_II_AdmGodk220121.pdf
   Google Scholar
• Ingeholm P, Gögenur I, Iversen LH. Danish colorectal cancer group database. Clin Epidemiol. 2016;8:465–468. doi: 10.2147/CLEP.S99481.
   PubMed Web of Science ®Google Scholar
• Rahbari NN, Weitz J, Hohenberger W, et al. Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the international study group of rectal cancer. Surgery. 2010;147(3):339–351. doi: 10.1016/J.SURG.2009.10.012.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8.
   PubMedGoogle Scholar
• Fisher S, Bennett C, Hennessy D, et al. Comparison of mortality hazard ratios associated with health behaviours in Canada and the United States: a population-based linked health survey study. BMC Public Health. 2022;22(1):478. doi: 10.1186/S12889-022-12849-Y/FIGURES/2.
   PubMed Web of Science ®Google Scholar
• Osterman E, Hammarström K, Imam I, et al. Completeness and accuracy of the registration of recurrences in the Swedish colorectal cancer registry (SCRCR) and an update of recurrence risk in colon cancer. Acta Oncol. 2021;60(7):842–849. doi: 10.1080/0284186X.2021.1896033.
   PubMed Web of Science ®Google Scholar
• Wilkinson NW, Yothers G, Lopa S, et al. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol. 2010;17(4):959–966. doi: 10.1245/S10434-009-0881-Y.
   PubMed Web of Science ®Google Scholar
• Casadaban L, Rauscher G, Aklilu M, et al. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer. 2016;122(21):3277–3287. doi: 10.1002/CNCR.30181.
   PubMed Web of Science ®Google Scholar
• Kumar A, Kennecke HF, Renouf DJ, et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer. 2015;121(4):527–534. doi: 10.1002/CNCR.29072.
   PubMed Web of Science ®Google Scholar
• Verhoeff SR, Van Erning FN, Lemmens VEPP, et al. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer. 2016;139(1):187–193. doi: 10.1002/IJC.30053.
   PubMed Web of Science ®Google Scholar
• Morton D, Seymour M, Magill L, et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol. 2023;41(8):1541–1552. doi: 10.1200/JCO.22.
   PubMed Web of Science ®Google Scholar
• Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872–877. doi: 10.1200/JCO.2008.19.5362.
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345(15):1091–1097. doi: 10.1056/NEJMOA010957.
   PubMed Web of Science ®Google Scholar
• Teufel A, Gerken M, Hartl J, et al. Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer. BMC Cancer. 2015;15(1):419. doi: 10.1186/S12885-015-1404-9.
   PubMedGoogle Scholar
• Gunderson LL, Jessup JM, Sargent DJ, et al. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;28(2):264–271. doi: 10.1200/JCO.2009.24.0952.
   PubMed Web of Science ®Google Scholar
• Belt EJT, Stockmann HBAC, Abis GSA, et al. Peri-operative bowel perforation in early stage colon cancer is associated with an adverse oncological outcome. J Gastrointest Surg. 2012;16(12):2260–2266. doi: 10.1007/S11605-012-2053-9.
   PubMed Web of Science ®Google Scholar
• Krarup PM, Nordholm-Carstensen A, Jorgensen LN, et al. Anastomotic leak increases distant recurrence and long-term mortality after curative resection for colonic cancer: a nationwide cohort study. Ann Surg. 2014;259(5):930–938. doi: 10.1097/SLA.0B013E3182A6F2FC.
   PubMed Web of Science ®Google Scholar
• Nitsche U, Zimmermann A, Späth C, et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann Surg. 2013;258(5):775–783. doi: 10.1097/SLA.0B013E3182A69F7E.
   PubMed Web of Science ®Google Scholar
• Ronnow CF, Arthursson V, Toth E, et al. Lymphovascular infiltration, not depth of invasion, is the critical risk factor of metastases in early colorectal cancer: retrospective population-based cohort study on prospectively collected data, including validation. Ann Surg. 2022;275(1):E148–E154. doi: 10.1097/SLA.0000000000003854.
   PubMed Web of Science ®Google Scholar
• Iveson TJ, Sobrero AF, Yoshino T, et al. Duration of adjuvant doublet chemotherapy (3 or 6 months) in patients with high-risk stage II colorectal cancer. J Clin Oncol. 2021;39(6):631–641. doi: 10.1200/JCO.20.01330.
   PubMed Web of Science ®Google Scholar
• Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261–2272. doi: 10.1056/NEJMOA2200075.
   PubMed Web of Science ®Google Scholar